Skip to main content
    X

    Xenetic Biosciences Inc (XBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.54
    +0.05 (+3.36%)

    Market Cap: $3.49M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Xenetic Biosciences Inc (XBIO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Xenetic Biosciences (XBIO) has a market cap of $3.49M. Its share count is up 51.94% from a year earlier. It holds $5.81M more cash than debt, 166.40% of its market cap.

    Total Valuation

    Market Cap$3.49M
    Latest price (Nov 17, 2026)$1.54

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.13% in the quarter ended Sep 30, 2026 and grew 23.28% a year over 2 years.

    Shares Outstanding2.34M
    Shares Change (YoY)+51.94%
    Shares Change (QoQ)+2.13%
    Share Count Growth (2Y CAGR)+23.28%

    Valuation Ratios

    Sales and book value multiples are 1.2x and 0.8x. Its year-end P/S ranged from 1.2x to 43.2x from 2017 to 2025.

    P/S Ratio1.2x
    P/B Ratio0.8x

    Valuation history and multiples

    Price Statistics

    The stock is down 40.77% over 52 weeks and trades 33.04% below its 50-day average.

    Beta (1Y)1.55
    52-Week Change-40.77%
    1-Month Change-20.21%
    3-Month Change-54.17%
    6-Month Change-46.90%
    5-Year Change-87.72%
    10-Year Change-99.63%
    Total Return (1Y)-40.77%
    Total Return (3Y CAGR)-21.63%
    Total Return (5Y CAGR)-35.89%
    Return vs SPY (1Y)-51.64%
    Max Drawdown (1Y)-68.09%
    Max Drawdown (3Y)-85.62%
    Sharpe Ratio (1Y)-0.52
    Correlation with SPY (1Y)0.21
    50-Day Average$2.30
    200-Day Average$2.80
    52-Week Range$1.43 to $4.94
    RSI (14 Days)31.5
    Average Volume (20 Days)23.79K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.15x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.15x
    Quick Ratio3.15x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on Assets (ROA)-57.94%
    ROE (5Y Average)-44.62%
    ROA (5Y Average)-40.28%
    ROIC (5Y Average)-41.01%

    Scores

    XBIO has an Altman Z-Score of -43.95, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-43.95
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Balance Sheet

    Cash and Equivalents$5.81M
    Total Debt$0
    Net Cash$5.81M
    Net Cash Per Share$2.48

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Growth

    Revenue grew 20.36% a year over 3 years.

    Revenue Growth (3Y CAGR)+20.36%
    Revenue Growth (5Y CAGR)+46.78%
    Book Value Per Share Growth (2Y CAGR)-28.83%
    Tangible Book Per Share Growth (2Y CAGR)-28.83%

    Revenue and profit by year

    Stock Splits

    The last split was a 1-for-10 reverse split on May 15, 2023.

    Last Split DateMay 15, 2023
    Split TypeReverse split
    Split Ratio1:10

    Analyst Forecast

    Consensus estimates put revenue growth at -20.06% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-20.06%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About XBIO

    What is XBIO's market cap?

    Xenetic Biosciences has a market cap of $3.49M.

    How many shares of XBIO are outstanding?

    Xenetic Biosciences has 2.34M shares outstanding. The count is up 51.94% from a year earlier.

    Does XBIO pay a dividend?

    No. Xenetic Biosciences does not pay a dividend.

    How much debt does XBIO have?

    Xenetic Biosciences has $0 of total debt and $5.81M of cash and equivalents, a net cash position of $5.81M.